BioDelivery Sciences International Inc
F:BD5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
US |
|
Carmax Inc
NYSE:KMX
|
US |
|
Zoy Home Furnishing Co Ltd
SSE:603709
|
CN |
|
Is Yatirim Menkul Degerler AS
IST:ISMEN.E
|
TR |
|
E
|
Ege Endustri ve Ticaret AS
IST:EGEEN.E
|
TR |
|
K
|
Konndor Industries Ltd
BSE:532397
|
IN |
|
S
|
Shaanxi Lighte Optoelectronics Material Co Ltd
SSE:688150
|
CN |
|
L
|
Luxchem Corporation Bhd
KLSE:LUXCHEM
|
MY |
|
Integra Resources Corp
XTSX:ITR
|
CA |
|
G
|
GSE Co Ltd
KOSDAQ:053050
|
KR |
|
Digital China Holdings Ltd
HKEX:861
|
HK |
BioDelivery Sciences International Inc
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
